Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
-4.35%
1 month
0%
YTD
-13.5%
1 year
-43.78%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Technology
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
04 December 24 |
Investor presentation
×
Investor presentation |
26 November 24 |
LOI with Metronomic to develop postpartum care in US
×
LOI with Metronomic to develop postpartum care in US |
20 November 24 |
Letter to Shareholders/Notice of General Meeting/Proxy Form
×
Letter to Shareholders/Notice of General Meeting/Proxy Form |
11 November 24 |
HeraMED completes further $1million placement
×
HeraMED completes further $1million placement |
11 November 24 |
Proposed issue of securities - HMD
×
Proposed issue of securities - HMD |
29 October 24 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
29 October 24 |
Cleansing Prospectus
×
Cleansing Prospectus |
29 October 24 |
Application for quotation of securities - HMD
×
Application for quotation of securities - HMD |
23 October 24 |
HeraMED completes $3.1 million placement
×
HeraMED completes $3.1 million placement |
23 October 24 |
Proposed issue of securities - HMD
×
Proposed issue of securities - HMD |
23 October 24 |
Proposed issue of securities - HMD
×
Proposed issue of securities - HMD |
21 October 24 |
Pause in Trading
×
Pause in Trading |
21 October 24 |
Trading Halt
×
Trading Halt |
08 October 24 |
HeraCARE user growth continues to rise
×
HeraCARE user growth continues to rise |
04 October 24 |
Notification of cessation of securities - HMD
×
Notification of cessation of securities - HMD |
27 September 24 |
HeraBEAT TGA regulatory classification to be upgraded
×
HeraBEAT TGA regulatory classification to be upgraded |
23 September 24 |
Letter of Intent with Founda Health
×
Letter of Intent with Founda Health |
28 August 24 |
Appendix 4D and Half Year Report
×
Appendix 4D and Half Year Report |
12 August 24 |
Change of Registry Address
×
Change of Registry Address |
30 July 24 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
23 July 24 |
Update to Managing Director & CEO Remuneration Package
×
Update to Managing Director & CEO Remuneration Package |
15 July 24 |
UTS Strategic Partnership
×
UTS Strategic Partnership |
04 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
28 June 24 |
Change of Director's Interest Notice AG DH TC
×
Change of Director's Interest Notice AG DH TC |
28 June 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.